

GLAXOSMITHKLINE PLC
Form 6-K
March 21, 2014

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending March 2014

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

-

Issued: 21 March 2014, London, UK - LSE Announcement

GSK publishes historical quarterly restated financial information

As previously announced, for 2014, GlaxoSmithKline (LSE:GSK) will adopt a revised presentation for the analysis of its Pharmaceuticals and Vaccines turnover by segment, product and therapeutic area that identifies revenues from an Established Products Portfolio as a new segment. This new segment comprises a portfolio of over 50 tail brands.

GSK has also announced its intention to report core results performance for 2014 measured against 2013 core results excluding the results attributable to divestments completed during 2013. In addition to reporting core results, GSK will continue to report its total results measured against 2013 total results.

The revised reporting approach reflects the financial information provided to the Chief Executive Officer and the responsibilities of the Corporate Executive Team (CET).

In addition, the classification of certain products has been changed in 2014, including:

- The transfer of the OTC dermatology brands acquired with the Stiefel business from the Pharmaceuticals and Vaccines business to the Consumer Healthcare business in the majority of emerging markets;
- The combination of certain previous therapeutic categories into a new therapeutic category presentation that reflects the key areas of focus for the business and the impact of the transfer of the majority of the brands in some therapeutic areas into the new Established Products Portfolio;
- The transfer of the OTC vitamins brands from inclusion under the Wellness category in Consumer Healthcare to inclusion under the Nutrition category.

In 2014, GSK also intends to report Pharmaceuticals and Vaccines turnover by product for the Japan segment. The previous EMAP segment is now named Emerging Markets.

In order to assist future comparability with historical data, for each quarter since the period ended 31 March 2013, and for the full years 2012 and 2013, this release includes the following information presented on a like-for-like basis with the classifications that will be reported in 2014:

- Core results excluding the results attributable to divestments completed during 2013;
- Pharmaceuticals and Vaccines turnover by product and region (excluding turnover attributable to divestments completed during 2013);
- Consumer Healthcare turnover by category and region (excluding turnover attributable to divestments completed during 2013);

CER growth rates have been calculated for 2013 excluding the impact on the growth rate of the divestments completed in 2013 but including the impact of divestments completed in earlier periods.

An Excel version of this data will be available on www.gsk.com/investors.

V A Whyte
Company Secretary
21 March 2014

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

GSK enquiries:

UK Media enquiries: David Mawdsley +44 (0) 20 8047 5502 (London)
Simon Steel +44 (0) 20 8047 5502 (London)

US Media enquiries: Stephen Rea +1 215 751 4394 (Philadelphia)
Melinda Stubbee +1 919 483 2510 (North Carolina)

Analyst/Investor enquiries:

Ziba Shamsi +44 (0) 20 8047 5543 (London)
Tom Curry +1 215 751 5419 (Philadelphia)
Gary Davies +44 (0) 20 8047 5503 (London)
James Dodwell +44 (0) 20 8047 2406 (London)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Lucy Singah +44 (0) 20 8047 2248 (London)

CER growth

In order to illustrate underlying performance, it is the Group's practice to discuss its results in terms of constant exchange rate (CER) growth. This represents growth calculated as if the exchange rates used to determine the results of overseas companies in Sterling had remained unchanged from those used in the comparative period.

Core results

Core results exclude the following items from total results: amortisation and impairment of intangible assets (excluding computer software) and goodwill; major restructuring costs, including those costs following material acquisitions; legal charges (net of insurance recoveries) and expenses on the settlement of litigation and government investigations, and acquisition accounting adjustments relating to the consolidation of material acquisitions, disposals of associates, products and businesses, other operating income other than royalty income and other items, together with the tax effects of all of

these items. GSK believes this approach provides a clearer view of the underlying performance of the core business and should make the Group's results more comparable with the majority of its peers.

Reconciliations of core results as previously reported to total results for 2013 have been included in an appendix to this document.

Brand names and partner acknowledgements

Brand names appearing in italics throughout this document are trademarks of GSK or associated companies or used under licence by the Group.

This Announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The information for 2013 has been derived from the full Group accounts published in the Annual Report 2013.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2013.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

| Group turnover by segment | 2013 | | Q4 2013 | |
|---|--------|-------------|---------|-------------|
| | £m | Growth CER% | £m | Growth CER% |
| Pharmaceuticals and Vaccines | | | | |
| -US | 5,817 | 4 | 1,514 | 11 |
| -Europe | 4,226 | 3 | 1,100 | - |
| -Emerging Markets | 3,370 | 3 | 983 | 9 |
| -Japan | 1,058 | 6 | 316 | 26 |
| -ViiV Healthcare | 1,386 | - | 385 | 15 |
| -Established Products | 3,874 | (8) | 947 | (9) |
| - Other trading and unallocated pharmaceuticals | 1,115 | 11 | 328 | 26 |
| Pharmaceuticals and Vaccines | 20,846 | 1 | 5,573 | 6 |
| Consumer Healthcare | 4,756 | 2 | 1,127 | - |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | |
|--|--------|---|-------|---|
| Segment turnover excluding divestments | 25,602 | 2 | 6,700 | 5 |
| Segment turnover including divestments | 26,505 | 1 | 6,906 | 5 |

| | 9 months 2013 | | Q3 2013 | |
|---|---------------|-------------|---------|-------------|
| | £m | Growth CER% | £m | Growth CER% |
| Pharmaceuticals and Vaccines | | | | |
| -US | 4,303 | 2 | 1,522 | 4 |
| -Europe | 3,126 | 4 | 1,049 | 9 |
| -Emerging Markets | 2,387 | 1 | 781 | (7) |
| -Japan | 742 | (1) | 210 | 3 |
| -ViiV Healthcare | 1,001 | (5) | 344 | (5) |
| -Established Products | 2,927 | (8) | 906 | (9) |
| - Other trading and unallocated pharmaceuticals | 787 | 6 | 272 | 10 |
| Pharmaceuticals and Vaccines | 15,273 | - | 5,084 | - |
| Consumer Healthcare | 3,629 | 3 | 1,190 | 4 |
| Segment turnover excluding divestments | 18,902 | - | 6,274 | 1 |
| Segment turnover including divestments | 19,599 | - | 6,510 | 1 |

| | 6 months 2013 | | Q2 2013 | |
|---|---------------|-------------|---------|-------------|
| | £m | Growth CER% | £m | Growth CER% |
| Pharmaceuticals and Vaccines | | | | |
| -US | 2,781 | 1 | 1,439 | 11 |
| -Europe | 2,077 | 2 | 1,060 | 4 |
| -Emerging Markets | 1,606 | 6 | 840 | 3 |
| -Japan | 532 | (3) | 229 | 3 |
| -ViiV Healthcare | 657 | (5) | 339 | (4) |
| -Established Products | 2,021 | (8) | 1,018 | (10) |
| - Other trading and unallocated pharmaceuticals | 515 | 4 | 260 | 4 |
| Pharmaceuticals and Vaccines | 10,189 | - | 5,185 | 2 |
| Consumer Healthcare | 2,439 | 2 | 1,188 | 2 |
| Segment turnover excluding divestments | 12,628 | - | 6,373 | 2 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | |
|--|--------|---|-------|---|
| Segment turnover including divestments | 13,089 | - | 6,618 | 2 |
|--|--------|---|-------|---|

| | Q1 2013 | |
|--|---------|-------------|
| | £m | Growth CER% |
| Pharmaceuticals and Vaccines | | |
| -US | 1,342 | (7) |
| -Europe | 1,017 | 1 |
| -Emerging Markets | 766 | 9 |
| -Japan | 303 | (7) |
| -ViiV Healthcare | 318 | (5) |
| -Established Products | 1,003 | (5) |
| -Other trading and unallocated pharmaceuticals | 255 | 3 |
| Pharmaceuticals and Vaccines | 5,004 | (2) |
| Consumer Healthcare | 1,251 | 1 |
| Segment turnover excluding divestments | 6,255 | (2) |
| Segment turnover including divestments | 6,471 | (2) |

| | 2012 | |
|--|--------|--|
| | £m | |
| Pharmaceuticals and Vaccines | | |
| -US | 5,508 | |
| -Europe | 3,956 | |
| -Emerging Markets | 3,309 | |
| -Japan | 1,203 | |
| -ViiV Healthcare | 1,374 | |
| -Established Products | 4,351 | |
| -Other trading and unallocated pharmaceuticals | 1,035 | |
| Pharmaceuticals and Vaccines | 20,736 | |
| Consumer Healthcare | 4,747 | |
| Segment turnover excluding 2013 divestments | 25,483 | |
| Segment turnover including 2013 divestments | 26,431 | |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pharmaceuticals and Vaccines turnover
Twelve months ended 31 December 2013

| | Total | | USA | | Europe | | Emerging Markets | | Japan | |
|--|-------|------|-------|------|--------|------|------------------|------|-------|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 7,289 | 4 | 3,594 | 7 | 1,802 | (2) | 837 | 4 | 554 | 10 |
| Avamys/Veramyst | 249 | 5 | 42 | (29) | 69 | 8 | 71 | 16 | 49 | 28 |
| Flixotide/Flovent | 796 | 2 | 482 | 6 | 117 | (7) | 58 | 7 | 42 | (7) |
| Relvar/Breo | 8 | - | 5 | - | - | - | - | - | 3 | - |
| Seretide/Advair | 5,274 | 4 | 2,769 | 8 | 1,458 | (2) | 429 | 4 | 277 | 8 |
| Ventolin | 642 | 2 | 291 | 4 | 127 | (2) | 171 | 2 | 9 | - |
| Other | 320 | 4 | 5 | (69) | 31 | (6) | 108 | (1) | 174 | 14 |
| Oncology | 969 | 22 | 380 | 17 | 339 | 28 | 149 | 18 | 63 | 36 |
| Arzerra | 75 | 23 | 46 | 18 | 27 | 29 | - | - | 1 | - |
| Mekinist | 10 | - | 10 | - | - | - | - | - | - | - |
| Promacta | 186 | 46 | 73 | 33 | 55 | 47 | 22 | 92 | 30 | 44 |
| Tafinlar | 16 | - | 11 | - | 4 | - | - | - | - | - |
| Tyverb/Tykerb | 207 | (13) | 55 | (21) | 82 | (9) | 47 | (9) | 17 | (5) |
| Votrient | 331 | 80 | 144 | 56 | 130 | 91 | 37 | 77 | 9 | >100 |
| Other | 144 | (23) | 41 | (40) | 41 | (17) | 43 | 2 | 6 | (25) |
| Cardiovascular, metabolic and urology (CVMU) | 1,073 | (5) | 456 | (27) | 308 | 18 | 135 | 27 | 114 | 25 |
| Avodart | 857 | 10 | 312 | (3) | 273 | 15 | 104 | 27 | 114 | 25 |
| Other | 216 | (40) | 144 | (53) | 35 | 48 | 31 | 24 | - | - |
| Immuno-inflammation | 161 | >100 | 148 | >100 | 8 | 100 | 1 | - | - | - |
| Benlysta | 146 | >100 | 134 | >100 | 8 | 100 | 1 | - | - | - |
| Other | 15 | - | 14 | - | - | - | - | - | - | - |
| Other | 2,674 | 5 | 261 | (25) | 720 | 2 | 1,124 | 2 | 291 | 36 |
| Dermatology | 631 | (5) | 115 | (37) | 170 | 6 | 289 | 8 | 28 | 3 |
| Augmentin | 630 | 5 | 1 | - | 203 | (3) | 393 | 11 | 13 | (6) |
| Other anti-bacterials | 224 | (4) | 7 | - | 66 | 5 | 148 | (4) | 3 | - |
| Rare diseases | 495 | 7 | 113 | (4) | 129 | 1 | 48 | 2 | 184 | 18 |
| Other | 694 | 18 | 25 | (37) | 152 | 6 | 246 | (11) | 63 | >100 |
| Vaccines | 3,420 | 2 | 978 | 17 | 1,049 | 3 | 1,124 | 1 | 36 | (76) |
| Boostrix | 288 | 19 | 183 | 23 | 65 | 19 | 20 | 25 | - | - |
| Cervarix | 172 | (37) | 6 | - | 61 | 11 | 92 | 23 | 10 | (90) |
| Fluarix, FluLaval | 251 | 25 | 146 | 65 | 35 | (21) | 43 | (2) | - | - |
| Hepatitis | 629 | (4) | 263 | (3) | 198 | (3) | 123 | (2) | - | - |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|-----------------------|--------|------|-------|-------|-------|------|-------|------|-------|------|
| Infanrix, Pediarix | 862 | 9 | 271 | 23 | 398 | 2 | 132 | 11 | - | - |
| Rotarix | 375 | 5 | 108 | 7 | 59 | 49 | 164 | 3 | 25 | (30) |
| Synflorix | 405 | 2 | - | - | 48 | 2 | 350 | 1 | - | - |
| Other | 438 | (4) | 1 | (100) | 185 | 2 | 200 | (14) | 1 | - |
| Innovative products | 15,586 | 4 | 5,817 | 4 | 4,226 | 3 | 3,370 | 3 | 1,058 | 6 |
| ViiV Healthcare (HIV) | 1,386 | - | 552 | 5 | 526 | (3) | 171 | (12) | 54 | 14 |
| Combivir | 116 | (36) | 35 | 46 | 39 | (41) | 35 | (56) | 3 | (11) |
| Epzicom/Kivexa | 763 | 14 | 269 | 9 | 328 | 11 | 78 | 38 | 36 | 21 |
| Lexiva/Agenerase | 113 | (11) | 62 | (10) | 27 | (22) | 18 | (1) | 3 | (7) |
| Selzentry | 143 | 10 | 58 | 1 | 63 | 8 | 6 | 67 | 3 | 49 |
| Tivicay | 19 | - | 19 | - | - | - | - | - | - | - |
| Trizivir | 97 | (10) | 58 | (6) | 32 | (17) | 4 | (26) | - | - |
| Other | 135 | (20) | 51 | (25) | 37 | (26) | 30 | (8) | 9 | (5) |
| Established products | 3,874 | (8) | 1,300 | (7) | 718 | (14) | 1,157 | (5) | 595 | (5) |
| Coreg | 131 | (2) | 130 | (2) | - | - | - | - | - | - |
| Hepsera | 96 | (21) | - | - | - | - | 70 | (28) | 25 | (3) |
| Imigran/Imitrex | 188 | 1 | 80 | 11 | 63 | (7) | 7 | - | 24 | (13) |
| Lamictal | 557 | (7) | 276 | (18) | 110 | (4) | 78 | 8 | 83 | 28 |
| Lovaza | 584 | (5) | 581 | (5) | - | - | - | - | - | - |
| Requip | 125 | (18) | 7 | (63) | 52 | (33) | 14 | - | 51 | 11 |
| Serevent | 129 | (10) | 51 | (2) | 55 | (17) | 4 | 33 | 13 | (20) |
| Seroxat/Paxil | 285 | (16) | - | - | 53 | (11) | 79 | (4) | 138 | (22) |
| Valtrex | 224 | (2) | 45 | 26 | 29 | (15) | 40 | 11 | 106 | (2) |
| Zeffix | 182 | (26) | 13 | (13) | 12 | (25) | 140 | (28) | 16 | (5) |
| Other | 1,373 | (6) | 117 | (5) | 344 | (14) | 725 | 2 | 139 | (5) |
| | 20,846 | 1 | | | | | | | | |

The table above includes the sales by product reported in the Other trading and unallocated pharmaceuticals segment (which includes Canada, Puerto Rico, Australasia, central vaccine tender sales and contract manufacturing sales) in the total column only.

Pharmaceuticals and Vaccines turnover
Three months ended 31 December 2013

| | Total | | USA | | Europe | | Emerging Markets | | Japan | |
|-------------------|-------|------|-----|------|--------|------|------------------|------|-------|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,923 | 7 | 958 | 14 | 454 | (4) | 227 | 4 | 152 | 13 |
| Avamys/Veramyst | 54 | (5) | 6 | (56) | 16 | 23 | 18 | 6 | 9 | 38 |
| Flixotide/Flovent | 209 | 4 | 124 | 8 | 30 | (9) | 17 | 13 | 12 | - |
| Relvar/Breo | 8 | - | 5 | - | - | - | - | - | 3 | - |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|--|-------|------|-------|--------|-------|------|-----|------|-----|------|
| Seretide/Advair | 1,398 | 9 | 741 | 17 | 368 | (4) | 119 | 6 | 82 | 11 |
| Ventolin | 175 | 1 | 80 | 3 | 33 | (6) | 47 | 6 | 3 | - |
| Other | 79 | (1) | 2 | (47) | 7 | (25) | 26 | (10) | 43 | 10 |
| Oncology | 266 | 24 | 102 | 21 | 89 | 26 | 46 | 22 | 16 | 31 |
| Arzerra | 19 | 36 | 13 | 30 | 5 | 25 | - | - | - | - |
| Mekinist | 7 | - | 7 | - | - | - | - | - | - | - |
| Promacta | 52 | 42 | 19 | 27 | 16 | 45 | 6 | 75 | 8 | 43 |
| Tafinlar | 11 | - | 6 | - | 4 | - | - | - | - | - |
| Tyverb/Tykerb | 49 | (18) | 11 | (35) | 19 | (10) | 14 | - | 4 | - |
| Votrient | 90 | 48 | 39 | 34 | 35 | 55 | 11 | 33 | 2 | >100 |
| Other | 38 | (12) | 7 | (37) | 10 | (19) | 15 | 23 | 2 | (33) |
| Cardiovascular, metabolic and urology (CVMU) | 283 | 14 | 116 | 4 | 81 | 13 | 36 | 39 | 33 | 25 |
| Avodart | 226 | 13 | 80 | 1 | 72 | 13 | 27 | 43 | 33 | 25 |
| Other | 57 | 19 | 36 | 10 | 9 | 13 | 9 | 29 | - | - |
| Immuno-inflammation | 46 | 59 | 41 | 57 | 2 | 50 | - | - | - | - |
| Benlysta | 37 | 28 | 33 | 26 | 2 | 50 | - | - | - | - |
| Other | 9 | - | 8 | - | - | - | - | - | - | - |
| Other | 756 | 7 | 54 | (49) | 199 | (3) | 285 | (3) | 107 | 72 |
| Dermatology | 135 | (17) | 13 | (71) | 42 | (2) | 67 | 3 | 7 | 13 |
| Augmentin | 165 | 3 | 1 | - | 53 | (4) | 101 | 6 | 4 | - |
| Other anti-bacterials | 57 | (11) | 2 | - | 18 | 6 | 36 | (11) | 1 | - |
| Rare diseases | 130 | (1) | 27 | (24) | 34 | 3 | 14 | (7) | 49 | 11 |
| Other | 269 | 43 | 11 | (53) | 52 | (10) | 67 | (15) | 46 | >100 |
| Vaccines | 967 | 12 | 243 | 23 | 275 | - | 389 | 22 | 8 | (44) |
| Boostrix | 91 | 65 | 65 | 97 | 15 | 7 | 7 | 40 | - | - |
| Cervarix | 45 | 2 | 1 | - | 19 | 38 | 25 | 18 | (1) | - |
| Fluarix, FluLaval | 87 | 76 | 36 | >100 | 21 | (23) | 22 | >100 | - | - |
| Hepatitis | 152 | (4) | 55 | (7) | 52 | 2 | 34 | 12 | - | - |
| Infanrix, Pediarix | 208 | (11) | 61 | (10) | 101 | (4) | 32 | (33) | - | - |
| Rotarix | 100 | 17 | 24 | (4) | 15 | 50 | 46 | 31 | 8 | - |
| Synflorix | 161 | 49 | - | - | 12 | (8) | 147 | 58 | - | - |
| Other | 123 | (3) | 1 | <(100) | 40 | - | 76 | 1 | 1 | - |
| Innovative products | 4,241 | 10 | 1,514 | 11 | 1,100 | - | 983 | 9 | 316 | 26 |
| ViiV Healthcare (HIV) | 385 | 15 | 171 | 30 | 135 | 1 | 41 | 7 | 15 | 13 |
| Combivir | 31 | (26) | 11 | 27 | 7 | (52) | 11 | (32) | - | (11) |
| Epzicom/Kivexa | 211 | 28 | 80 | 35 | 88 | 15 | 18 | 70 | 10 | 18 |
| Lexiva/Agenerase | 28 | (9) | 18 | 2 | 6 | (23) | 3 | (38) | - | (5) |
| Selzentry | 37 | (3) | 14 | (16) | 17 | 11 | 1 | (4) | - | 28 |
| Tivicay | 15 | - | 15 | - | - | - | - | - | - | - |
| Trizivir | 26 | - | 16 | 2 | 7 | (11) | 1 | >100 | - | - |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|----------------------|-------|-------|-----|------|-----|------|-----|------|-----|------|
| Other | 37 | 12 | 17 | 32 | 10 | (11) | 7 | 33 | 5 | 2 |
| Established products | 947 | (9) | 321 | (10) | 176 | (11) | 275 | (7) | 150 | 1 |
| Coreg | 29 | (3) | 29 | - | - | - | - | - | - | - |
| Hepsera | 23 | (27) | - | - | - | - | 15 | (36) | 6 | - |
| Imigran/Imitrex | 46 | - | 18 | 6 | 15 | (6) | 2 | - | 6 | (13) |
| Lamictal | 152 | (3) | 77 | (15) | 28 | - | 20 | 16 | 23 | 26 |
| Lovaza | 140 | (5) | 139 | (5) | - | - | - | - | - | - |
| Requip | 29 | (3) | 1 | - | 11 | (29) | 3 | - | 14 | 13 |
| Serevent | 31 | (9) | 13 | (8) | 14 | (13) | 1 | - | 3 | (20) |
| Seroxat/Paxil | 69 | (14) | - | - | 12 | (27) | 19 | (9) | 35 | (9) |
| Valtrex | 59 | (7) | 15 | (30) | 7 | 17 | 10 | 22 | 26 | - |
| Zeffix | 43 | (30) | 3 | (40) | 3 | - | 33 | (31) | 4 | - |
| Other | 326 | (10) | 26 | (18) | 86 | (11) | 172 | (1) | 33 | 2 |
| | ----- | ----- | | | | | | | | |
| | 5,573 | 6 | | | | | | | | |
| | ----- | ----- | | | | | | | | |

The table above includes the sales by product reported in the Other trading and unallocated pharmaceuticals segment (which includes Canada, Puerto Rico, Australasia, central vaccine tender sales and contract manufacturing sales) in the total column only.

Pharmaceuticals and Vaccines turnover
Three months ended 30 September 2013

| | Total | | USA | | Europe | | Emerging Markets | | Japan | |
|--|-------|------|-----|------|--------|------|------------------|------|-------|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,640 | (2) | 816 | (3) | 418 | (1) | 182 | (6) | 105 | 6 |
| Avamys/Veramyst | 55 | 8 | 13 | (14) | 13 | 8 | 20 | 31 | 5 | (13) |
| Flixotide/Flovent | 172 | (7) | 105 | (8) | 25 | (4) | 12 | - | 9 | (8) |
| Relvar/Breo | - | - | - | - | - | - | - | - | - | - |
| Seretide/Advair | 1,209 | (1) | 632 | (1) | 344 | (1) | 87 | (12) | 62 | 8 |
| Ventolin | 145 | (5) | 66 | (10) | 29 | - | 39 | 3 | 2 | 50 |
| Other | 59 | (2) | - | - | 7 | - | 24 | (18) | 27 | 9 |
| Oncology | 249 | 23 | 99 | 14 | 91 | 32 | 36 | 19 | 16 | 36 |
| Arzerra | 18 | (11) | 13 | 20 | 4 | (50) | - | - | 1 | - |
| Mekinist | 3 | - | 3 | - | - | - | - | - | - | - |
| Promacta | 49 | 43 | 19 | 27 | 15 | 56 | 6 | 100 | 8 | 43 |
| Tafinlar | 4 | - | 4 | - | - | - | - | - | - | - |
| Tyverb/Tykerb | 53 | (7) | 14 | (18) | 21 | (10) | 12 | 8 | 4 | (17) |
| Votrient | 91 | 84 | 36 | 38 | 39 | >100 | 10 | 100 | 3 | - |
| Other | 31 | (26) | 10 | (51) | 12 | 10 | 8 | (27) | - | - |
| Cardiovascular, metabolic and urology | 262 | 7 | 110 | (6) | 76 | 20 | 33 | 14 | 28 | 30 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

(CVMU)

| | | | | | | | | | | |
|-----------------------|-------|------|-------|------|-------|------|-----|------|-----|------|
| Avodart | 207 | 6 | 73 | (11) | 67 | 17 | 26 | 13 | 28 | 30 |
| Other | 55 | 11 | 37 | 6 | 9 | 60 | 7 | 17 | - | - |
| Immuno-inflammation | 48 | >100 | 45 | >100 | 2 | 100 | 1 | - | - | - |
| Benlysta | 42 | >100 | 39 | 100 | 2 | 100 | 1 | - | - | - |
| Other | 6 | - | 6 | - | - | - | - | - | - | - |
| Other | 648 | 4 | 77 | (20) | 189 | 31 | 266 | (7) | 55 | 11 |
| Dermatology | 165 | 2 | 39 | (1) | 42 | 5 | 70 | 4 | 6 | - |
| Augmentin | 140 | 1 | - | - | 43 | 5 | 90 | 1 | 3 | - |
| Other anti-bacterials | 46 | (12) | 2 | 70 | 13 | 6 | 32 | (19) | 1 | - |
| Rare diseases | 125 | (1) | 30 | (26) | 32 | 7 | 13 | - | 45 | 14 |
| Other | 172 | 21 | 6 | (56) | 59 | >100 | 61 | (17) | - | - |
| Vaccines | 987 | 3 | 375 | 24 | 273 | 4 | 263 | (14) | 6 | (75) |
| Boostrix | 83 | 4 | 56 | (2) | 18 | 21 | 4 | 33 | - | - |
| Cervarix | 41 | (11) | 2 | (33) | 14 | 27 | 25 | 32 | - | - |
| Fluarix, FluLaval | 142 | 1 | 104 | 29 | 16 | (16) | 7 | (69) | - | - |
| Hepatitis | 168 | (1) | 81 | 5 | 48 | (4) | 29 | (15) | - | - |
| Infanrix, Pediarix | 258 | 26 | 100 | 69 | 98 | 1 | 44 | 26 | - | - |
| Rotarix | 108 | 5 | 32 | 19 | 17 | 78 | 50 | 2 | 6 | (56) |
| Synflorix | 80 | (28) | - | - | 12 | (8) | 66 | (32) | - | - |
| Other | 107 | 4 | - | - | 50 | 2 | 38 | (12) | - | - |
| Innovative products | 3,834 | 3 | 1,522 | 4 | 1,049 | 9 | 781 | (7) | 210 | 3 |
| ViiV Healthcare (HIV) | 344 | (5) | 136 | 3 | 124 | (7) | 51 | (26) | 13 | 13 |
| Combivir | 25 | (55) | 7 | 11 | 8 | (50) | 8 | (73) | 1 | (10) |
| Epzicom/Kivexa | 190 | 8 | 65 | (3) | 79 | 8 | 24 | 20 | 9 | 22 |
| Lexiva/Agenerase | 29 | (6) | 15 | (4) | 6 | (22) | 7 | 8 | 1 | (7) |
| Selzentry | 34 | 10 | 16 | 16 | 14 | 2 | 1 | 89 | 1 | 36 |
| Tivicay | 4 | - | 4 | - | - | - | - | - | - | - |
| Trizivir | 24 | (4) | 15 | (1) | 8 | (19) | 2 | (4) | - | - |
| Other | 38 | (13) | 14 | - | 9 | (37) | 9 | (7) | 1 | (8) |
| Established products | 906 | (9) | 320 | (3) | 172 | (14) | 245 | (18) | 149 | 1 |
| Coreg | 36 | 9 | 36 | 9 | - | - | - | - | - | - |
| Hepsera | 15 | (47) | - | - | - | - | 10 | (63) | 6 | (13) |
| Imigran/Imitrex | 47 | 2 | 21 | 18 | 15 | (6) | 1 | - | 6 | (22) |
| Lamictal | 139 | (6) | 70 | (16) | 27 | (4) | 19 | - | 21 | 30 |
| Lovaza | 135 | (12) | 134 | (12) | - | - | - | - | - | - |
| Requip | 36 | (5) | 3 | - | 13 | (37) | 4 | - | 15 | 29 |
| Serevent | 32 | (6) | 13 | 8 | 13 | (25) | 1 | - | 3 | (20) |
| Seroxat/Paxil | 64 | (9) | - | - | 12 | (8) | 16 | (16) | 34 | (5) |
| Valtrex | 55 | 17 | 10 | - | 8 | - | 11 | - | 26 | - |
| Zeffix | 27 | (57) | 3 | (25) | 3 | (25) | 16 | (69) | 4 | - |
| Other | 320 | (5) | 30 | 22 | 81 | (13) | 167 | (3) | 34 | (7) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

 5,084 -

The table above includes the sales by product reported in the Other trading and unallocated pharmaceuticals segment (which includes Canada, Puerto Rico, Australasia, central vaccine tender sales and contract manufacturing sales) in the total column only.

Pharmaceuticals and Vaccines turnover
 Three months ended 30 June 2013

| | Total | | USA | | Europe | | Emerging Markets | | Japan | |
|--|-------|------|-----|------|--------|------|------------------|------|-------|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,847 | 4 | 914 | 8 | 469 | (1) | 224 | 10 | 113 | (4) |
| Avamys/Veramyst | 60 | (6) | 12 | (20) | 23 | 5 | 17 | 6 | 3 | (38) |
| Flixotide/Flovent | 202 | 5 | 124 | 12 | 29 | (13) | 14 | - | 11 | (13) |
| Relvar/Breo | - | - | - | - | - | - | - | - | - | - |
| Seretide/Advair | 1,358 | 5 | 708 | 8 | 376 | (1) | 117 | 14 | 70 | 8 |
| Ventolin | 160 | 7 | 69 | 18 | 32 | - | 44 | - | 2 | - |
| Other | 67 | (9) | 1 | (54) | 9 | - | 32 | 19 | 27 | (17) |
| Oncology | 233 | 17 | 91 | 10 | 80 | 26 | 36 | 23 | 17 | 43 |
| Arzerra | 17 | 20 | 10 | 22 | 7 | 17 | - | - | - | - |
| Mekinist | - | - | - | - | - | - | - | - | - | - |
| Promacta | 45 | 53 | 19 | 38 | 13 | 50 | 5 | 67 | 8 | 50 |
| Tafinlar | 1 | - | 1 | - | - | - | - | - | - | - |
| Tyverb/Tykerb | 53 | (12) | 15 | (18) | 21 | (5) | 11 | (21) | 5 | - |
| Votrient | 79 | 97 | 36 | 70 | 30 | 100 | 9 | >100 | 2 | - |
| Other | 38 | (33) | 10 | (50) | 9 | (18) | 11 | 22 | 2 | - |
| Cardiovascular, metabolic and urology (CVMU) | 275 | 15 | 122 | 6 | 78 | 16 | 35 | 30 | 28 | 21 |
| Avodart | 221 | 12 | 84 | 1 | 68 | 10 | 27 | 35 | 28 | 21 |
| Other | 54 | 30 | 38 | 19 | 10 | 67 | 8 | 14 | - | - |
| Immuno-inflammation | 38 | >100 | 35 | >100 | 2 | - | - | - | - | - |
| Benlysta | 38 | >100 | 35 | >100 | 2 | - | - | - | - | - |
| Other | - | - | - | - | - | - | - | - | - | - |
| Other | 649 | 8 | 63 | - | 167 | 4 | 298 | 11 | 60 | 23 |
| Dermatology | 169 | 1 | 31 | (35) | 44 | 14 | 79 | 18 | 8 | - |
| Augmentin | 150 | - | - | - | 45 | (13) | 99 | 11 | 3 | (25) |
| Other anti-bacterials | 60 | 6 | 2 | 41 | 14 | 6 | 42 | 9 | - | - |
| Rare diseases | 127 | 21 | 29 | 53 | 32 | (3) | 12 | 20 | 48 | 27 |
| Other | 143 | 15 | 1 | (74) | 32 | 29 | 66 | 2 | 1 | - |
| Vaccines | 786 | - | 214 | 14 | 264 | 5 | 247 | (13) | 11 | (43) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|-----------------------|-------|------|-------|------|-------|------|-----|------|-----|------|
| Boostrix | 68 | 16 | 41 | 8 | 19 | 38 | 5 | 67 | - | - |
| Cervarix | 46 | (8) | 2 | 100 | 13 | (20) | 25 | 19 | 4 | (54) |
| Fluarix, FluLaval | 7 | 40 | 2 | 100 | (1) | 50 | 5 | - | - | - |
| Hepatitis | 170 | 1 | 73 | 3 | 52 | (4) | 36 | (3) | - | - |
| Infanrix, Pediarix | 218 | 18 | 72 | 31 | 103 | 8 | 28 | 27 | - | - |
| Rotarix | 87 | (8) | 25 | 9 | 16 | 60 | 37 | (23) | 6 | (20) |
| Synflorix | 74 | (31) | - | - | 12 | - | 60 | (37) | - | - |
| Other | 116 | (2) | (1) | - | 50 | (2) | 51 | (7) | 1 | - |
| Innovative products | 3,828 | 6 | 1,439 | 11 | 1,060 | 4 | 840 | 3 | 229 | 3 |
| ViiV Healthcare (HIV) | 339 | (4) | 119 | (4) | 136 | (1) | 50 | (17) | 14 | 11 |
| Combivir | 27 | (45) | 6 | 19 | 10 | (43) | 9 | (60) | 1 | (14) |
| Epzicom/Kivexa | 193 | 13 | 63 | 6 | 84 | 14 | 23 | 35 | 9 | 21 |
| Lexiva/Agenerase | 29 | (12) | 14 | (25) | 7 | (19) | 6 | 63 | 1 | (17) |
| Selzentry | 35 | 10 | 15 | 5 | 17 | 10 | 2 | 1 | 1 | 51 |
| Tivicay | - | - | - | - | - | - | - | - | - | - |
| Trizivir | 23 | (24) | 13 | (16) | 8 | (22) | 1 | - | - | - |
| Other | 32 | (18) | 8 | (26) | 10 | (6) | 9 | (22) | 2 | (11) |
| Established products | 1,018 | (10) | 331 | (11) | 175 | (16) | 321 | 1 | 153 | (14) |
| Coreg | 33 | (6) | 33 | (9) | - | - | - | - | - | - |
| Hepsera | 31 | (3) | - | - | - | - | 24 | (8) | 7 | - |
| Imigran/Imitrex | 47 | (8) | 19 | (14) | 16 | (11) | 2 | (50) | 6 | - |
| Lamictal | 133 | (8) | 63 | (18) | 27 | (10) | 20 | 5 | 21 | 25 |
| Lovaza | 161 | - | 161 | - | - | - | - | - | - | - |
| Requip | 29 | (30) | 1 | (83) | 13 | (37) | 3 | (25) | 12 | 7 |
| Serevent | 33 | (13) | 12 | - | 14 | (13) | 1 | - | 4 | (20) |
| Seroxat/Paxil | 79 | (24) | - | - | 15 | (7) | 21 | - | 37 | (37) |
| Valtrex | 55 | (9) | 9 | - | 7 | (30) | 10 | 11 | 28 | - |
| Zeffix | 55 | (12) | 4 | - | 3 | (25) | 44 | (11) | 4 | (17) |
| Other | 362 | (9) | 29 | (37) | 80 | (15) | 196 | 5 | 34 | (17) |
| | 5,185 | 2 | | | | | | | | |

The table above includes the sales by product reported in the Other trading and unallocated pharmaceuticals segment (which includes Canada, Puerto Rico, Australasia, central vaccine tender sales and contract manufacturing sales) in the total column only.

Pharmaceuticals and Vaccines turnover
Three months ended 31 March 2013

| | Total | | USA | | Europe | | Emerging Markets | | Japan | |
|-----------------|-------|------|-----|------|--------|------|------------------|------|-------|------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,879 | 6 | 906 | 7 | 461 | (2) | 204 | 8 | 184 | 24 |
| Avamys/Veramyst | 80 | 22 | 11 | (21) | 17 | - | 16 | 23 | 32 | 64 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|--|-------|------|-------|------|-------|------|-----|------|-----|------|
| Flixotide/Flovent | 213 | 7 | 129 | 13 | 33 | (3) | 15 | 15 | 10 | (8) |
| Relvar/Breo | - | - | - | - | - | - | - | - | - | - |
| Seretide/Advair | 1,309 | 4 | 688 | 8 | 370 | (2) | 106 | 8 | 63 | 4 |
| Ventolin | 162 | 4 | 76 | 9 | 33 | - | 41 | - | 2 | (33) |
| Other | 115 | 24 | 2 | (71) | 8 | - | 26 | 8 | 77 | 40 |
| Oncology | 221 | 23 | 88 | 24 | 79 | 26 | 31 | 7 | 14 | 33 |
| Arzerra | 21 | 67 | 10 | - | 11 | >100 | - | - | - | - |
| Mekinist | - | - | - | - | - | - | - | - | - | - |
| Promacta | 40 | 48 | 16 | 45 | 11 | 38 | 5 | >100 | 6 | 40 |
| Tafinlar | - | - | - | - | - | - | - | - | - | - |
| Tyverb/Tykerb | 52 | (13) | 15 | (12) | 21 | (13) | 10 | (23) | 4 | - |
| Votrient | 71 | >100 | 33 | >100 | 26 | 100 | 7 | 75 | 2 | - |
| Other | 37 | (19) | 14 | (18) | 10 | (33) | 9 | (10) | 2 | - |
| Cardiovascular, metabolic and urology (CVMU) | 253 | (37) | 108 | (62) | 73 | 24 | 31 | 24 | 25 | 22 |
| Avodart | 203 | 10 | 75 | (3) | 66 | 20 | 24 | 20 | 25 | 22 |
| Other | 50 | (78) | 33 | (84) | 7 | 75 | 7 | 40 | - | - |
| Immuno-inflammation | 29 | >100 | 27 | >100 | 2 | 100 | - | - | - | - |
| Benlysta | 29 | >100 | 27 | >100 | 2 | 100 | - | - | - | - |
| Other | - | - | - | - | - | - | - | - | - | - |
| Other | 621 | - | 67 | (20) | 165 | (14) | 275 | 9 | 69 | 29 |
| Dermatology | 162 | (6) | 32 | (37) | 42 | 11 | 73 | 7 | 7 | - |
| Augmentin | 175 | 16 | - | - | 62 | - | 103 | 27 | 3 | - |
| Other anti-bacterials | 61 | 3 | 1 | (58) | 21 | 3 | 38 | 5 | 1 | 23 |
| Rare diseases | 113 | 12 | 27 | 18 | 31 | (3) | 9 | - | 42 | 23 |
| Other | 110 | (18) | 7 | (13) | 9 | (77) | 52 | (9) | 16 | 86 |
| Vaccines | 680 | (11) | 146 | (3) | 237 | 4 | 225 | 7 | 11 | (88) |
| Boostrix | 46 | (4) | 21 | - | 13 | 8 | 4 | (20) | - | - |
| Cervarix | 40 | (69) | 1 | - | 15 | 7 | 17 | 23 | 7 | (93) |
| Fluarix, FluLaval | 15 | >100 | 4 | - | (1) | - | 9 | >100 | - | - |
| Hepatitis | 139 | (10) | 54 | (14) | 46 | (4) | 24 | (4) | - | - |
| Infanrix, Pediarix | 178 | 10 | 38 | - | 96 | 3 | 28 | 100 | - | - |
| Rotarix | 80 | 7 | 27 | 4 | 11 | 10 | 31 | 14 | 5 | (29) |
| Synflorix | 90 | 23 | - | - | 12 | 33 | 77 | 26 | - | - |
| Other | 92 | (15) | 1 | - | 45 | 8 | 35 | (42) | (1) | - |
| Innovative products | 3,683 | (1) | 1,342 | (7) | 1,017 | 1 | 766 | 9 | 303 | (7) |
| ViiV Healthcare (HIV) | 318 | (5) | 126 | (10) | 131 | (6) | 29 | 2 | 12 | 19 |
| Combivir | 33 | (6) | 11 | >100 | 14 | (23) | 7 | (32) | 1 | (7) |
| Epzicom/Kivexa | 169 | 6 | 61 | - | 77 | 6 | 13 | 46 | 8 | 25 |
| Lexiva/Agenerase | 27 | (16) | 15 | (10) | 8 | (23) | 2 | (31) | 1 | 5 |
| Selzentry | 37 | 28 | 13 | 4 | 15 | 11 | 2 | >100 | 1 | >100 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | | | | |
|----------------------|-------|-------|-----|------|-----|------|-----|------|-----|------|
| Tivicay | - | - | - | - | - | - | - | - | - | - |
| Trizivir | 24 | (11) | 14 | (7) | 9 | (15) | - | - | - | - |
| Other | 28 | (46) | 12 | (61) | 8 | (44) | 5 | (17) | 1 | (1) |
| Established products | 1,003 | (5) | 328 | (3) | 195 | (15) | 316 | 6 | 143 | (9) |
| Coreg | 33 | (9) | 32 | (9) | - | - | - | - | - | - |
| Hepsera | 27 | (7) | - | - | - | - | 21 | (5) | 6 | - |
| Imigran/Imitrex | 48 | 9 | 22 | 47 | 17 | (6) | 2 | 100 | 6 | (14) |
| Lamictal | 133 | (9) | 66 | (23) | 28 | (3) | 19 | 12 | 18 | 33 |
| Lovaza | 148 | (3) | 147 | (3) | - | - | - | - | - | - |
| Requip | 31 | (29) | 2 | (78) | 15 | (29) | 4 | 33 | 10 | (8) |
| Serevent | 33 | (13) | 13 | (8) | 14 | (18) | 1 | - | 3 | (20) |
| Seroxat/Paxil | 73 | (15) | - | - | 14 | - | 23 | 10 | 32 | (30) |
| Valtrex | 55 | (6) | 11 | 57 | 7 | (30) | 9 | 13 | 26 | (6) |
| Zeffix | 57 | (2) | 3 | 50 | 3 | (40) | 47 | 2 | 4 | - |
| Other | 365 | 1 | 32 | 72 | 97 | (15) | 190 | 6 | 38 | 2 |
| | ----- | ----- | | | | | | | | |
| | 5,004 | (2) | | | | | | | | |
| | ----- | ----- | | | | | | | | |

The table above includes the sales by product reported in the Other trading and unallocated pharmaceuticals segment (which includes Canada, Puerto Rico, Australasia, central vaccine tender sales and contract manufacturing sales) in the total column only.

Pharmaceuticals and Vaccines turnover
Twelve months ended 31 December 2012

| | Total | USA | Europe | Emerging Markets | Japan |
|-------------------|-------|-------|--------|---------------------|-------|
| | £m | £m | £m | £m | £m |
| | ----- | ----- | ----- | ----- | ----- |
| Respiratory | 7,044 | 3,331 | 1,789 | 815 | 604 |
| Avamys/Veramyst | 246 | 59 | 62 | 63 | 46 |
| Flixotide/Flovent | 779 | 448 | 122 | 55 | 55 |
| Relvar/Breo | - | - | - | - | - |
| Seretide/Advair | 5,046 | 2,533 | 1,447 | 417 | 309 |
| Ventolin | 631 | 277 | 126 | 171 | 11 |
| Other | 342 | 14 | 32 | 109 | 183 |
| Oncology | 798 | 321 | 256 | 131 | 56 |
| Arzerra | 60 | 38 | 21 | - | - |
| Mekinist | - | - | - | - | - |
| Promacta | 130 | 54 | 36 | 12 | 25 |
| Tafinlar | - | - | - | - | - |
| Tyverb/Tykerb | 239 | 68 | 87 | 54 | 22 |
| Votrient | 183 | 91 | 66 | 22 | 1 |
| Other | 186 | 70 | 46 | 43 | 8 |
| | 1,144 | 620 | 251 | 109 | 110 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Cardiovascular, metabolic and urology
(CVMU)

| | | | | | |
|-----------------------|--------|-------|-------|-------|-------|
| Avodart | 790 | 317 | 228 | 84 | 110 |
| Other | 354 | 303 | 23 | 25 | - |
| Immuno-inflammation | 70 | 65 | 4 | - | - |
| Benlysta | 70 | 65 | 4 | - | - |
| Other | - | - | - | - | - |
| Other | 2,630 | 345 | 676 | 1,147 | 257 |
| Dermatology | 680 | 181 | 155 | 279 | 33 |
| Augmentin | 608 | 1 | 202 | 367 | 16 |
| Other anti-bacterials | 233 | 7 | 60 | 158 | 3 |
| Rare diseases | 495 | 117 | 123 | 48 | 188 |
| Other | 614 | 39 | 136 | 295 | 17 |
| Vaccines | 3,325 | 826 | 980 | 1,107 | 176 |
| Boostrix | 238 | 147 | 53 | 16 | - |
| Cervarix | 270 | 6 | 53 | 75 | 132 |
| Fluarix, FluLaval | 200 | 88 | 43 | 44 | - |
| Hepatitis | 646 | 266 | 197 | 128 | - |
| Infanrix, Pediarix | 775 | 218 | 376 | 120 | - |
| Rotarix | 360 | 100 | 39 | 159 | 44 |
| Synflorix | 385 | - | 45 | 334 | - |
| Other | 451 | 1 | 174 | 231 | - |
| Innovative products | 15,011 | 5,508 | 3,956 | 3,309 | 1,203 |
| ViiV Healthcare (HIV) | 1,374 | 520 | 523 | 198 | 57 |
| Combivir | 179 | 24 | 64 | 79 | 4 |
| Epzicom/Kivexa | 665 | 243 | 285 | 57 | 36 |
| Lexiva/Agenerase | 127 | 68 | 33 | 19 | 3 |
| Selzentry | 128 | 57 | 56 | 4 | 3 |
| Tivicay | - | - | - | - | - |
| Trizivir | 107 | 61 | 37 | 5 | - |
| Other | 168 | 67 | 48 | 34 | 11 |
| Established products | 4,351 | 1,377 | 809 | 1,249 | 760 |
| Coreg | 133 | 132 | - | - | - |
| Hepsera | 126 | - | - | 95 | 31 |
| Imigran/Imitrex | 190 | 72 | 67 | 7 | 32 |
| Lamictal | 610 | 332 | 112 | 75 | 78 |
| Lovaza | 607 | 604 | - | - | - |
| Requip | 164 | 19 | 76 | 14 | 55 |
| Serevent | 145 | 51 | 64 | 3 | 20 |
| Seroxat/Paxil | 374 | (1) | 57 | 84 | 214 |
| Valtrex | 252 | 35 | 33 | 37 | 130 |
| Zeffix | 243 | 15 | 16 | 188 | 20 |
| Other | 1,507 | 118 | 384 | 746 | 180 |

 20,736

The table above includes the sales by product reported in the Other trading and unallocated pharmaceuticals segment (which includes Canada, Puerto Rico, Australasia, central vaccine tender sales and contract manufacturing sales) in the total column only.

Consumer Healthcare turnover

Twelve months ended 31 December 2013

| | £m | CER% |
|-------------|-------|-------|
| Wellness | 1,865 | (5) |
| Oral health | 1,884 | 6 |
| Nutrition | 627 | 12 |
| Skin health | 380 | 6 |
| | ----- | ----- |
| Total | 4,756 | 2 |
| | ----- | ----- |

| | | |
|--------|-------|-------|
| USA | 951 | 1 |
| Europe | 1,392 | (2) |
| ROW | 2,413 | 5 |
| | ----- | ----- |
| Total | 4,756 | 2 |
| | ----- | ----- |

Consumer Healthcare turnover

Three months ended 31 December 2013

| | £m | CER% |
|-------------|-------|-------|
| Wellness | 454 | (6) |
| Oral health | 447 | 4 |
| Nutrition | 130 | 11 |
| Skin health | 96 | 1 |
| | ----- | ----- |
| Total | 1,127 | - |
| | ----- | ----- |

| | | |
|--------|-------|-------|
| USA | 242 | (2) |
| Europe | 342 | (4) |
| ROW | 543 | 4 |
| | ----- | ----- |
| Total | 1,127 | - |
| | ----- | ----- |

Consumer Healthcare turnover
Three months ended 30 September 2013

| | £m | CER% |
|-------------|-------|-------|
| | ----- | ----- |
| Wellness | 464 | (1) |
| Oral health | 476 | 6 |
| Nutrition | 160 | 12 |
| Skin health | 90 | 11 |
| | ----- | ----- |
| Total | 1,190 | 4 |
| | ----- | ----- |

| | | |
|--------|-------|-------|
| USA | 233 | - |
| Europe | 353 | 4 |
| ROW | 604 | 6 |
| | ----- | ----- |
| Total | 1,190 | 4 |
| | ----- | ----- |

Consumer Healthcare turnover
Three months ended 30 June 2013

| | £m | CER% |
|-------------|-------|-------|
| | ----- | ----- |
| Wellness | 448 | (8) |
| Oral health | 481 | 8 |
| Nutrition | 162 | 14 |
| Skin health | 97 | 7 |
| | ----- | ----- |
| Total | 1,188 | 2 |
| | ----- | ----- |

| | | |
|--------|-------|-------|
| USA | 238 | 5 |
| Europe | 343 | (3) |
| ROW | 607 | 4 |
| | ----- | ----- |
| Total | 1,188 | 2 |
| | ----- | ----- |

Consumer Healthcare turnover
Three months ended 31 March 2013

£m CER%

| | | |
|-------------|-------|-----|
| Wellness | 499 | (5) |
| Oral health | 480 | 5 |
| Nutrition | 175 | 12 |
| Skin health | 97 | 6 |
| Total | 1,251 | 1 |
| USA | 238 | 3 |
| Europe | 354 | (5) |
| ROW | 659 | 5 |
| Total | 1,251 | 1 |

Consumer Healthcare turnover
Twelve months ended 31 December 2012

| | £m |
|-------------|-------|
| Wellness | 1,991 |
| Oral health | 1,806 |
| Nutrition | 590 |
| Skin health | 360 |
| Total | 4,747 |
| USA | 926 |
| Europe | 1,386 |
| ROW | 2,435 |
| Total | 4,747 |

Impact of Divestments on 2013 Core Results

| | Reported £m | FY 2013 Revised £m | Change £m |
|---------------|----------------|--------------------------|--------------|
| Turnover | 26,505 | 25,602 | (903) |
| Cost of sales | (7,549) | (7,075) | 474 |
| Gross profit | 18,956 | 18,527 | (429) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | |
|---|---------|---------|--------|
| Selling, general and administration | (7,928) | (7,749) | 179 |
| Research and development | (3,400) | (3,394) | 6 |
| Royalty income | 387 | 387 | - |
| | ----- | ----- | ----- |
| Operating profit | 8,015 | 7,771 | (244) |
| Net finance costs | (692) | (692) | - |
| Share of after tax profits of associates and joint ventures | 43 | 43 | - |
| | ----- | ----- | ----- |
| Profit before taxation | 7,366 | 7,122 | (244) |
| Taxation | (1,695) | (1,635) | 60 |
| Tax rate% | 23.0% | 23.0% | |
| | ----- | ----- | ----- |
| Profit after taxation | 5,671 | 5,487 | (184) |
| | ----- | ----- | ----- |
| Profit attributable to non-controlling interest | 250 | 250 | - |
| Profit attributable to shareholders | 5,421 | 5,237 | (184) |
| | ----- | ----- | ----- |
| Earnings per share | 112.2p | 108.4p | (3.8)p |
| Weighted average number of shares | 4,831 | 4,831 | |

| Reported 2013 Core Results | Q1 2013 £m | Q2 2013 £m | H1 2013 £m | Q3 2013 £m | 9M 2013 £m | Q4 2013 £m | FY 2013 £m |
|---|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Turnover | 6,471 | 6,618 | 13,089 | 6,510 | 19,599 | 6,906 | 26,505 |
| Cost of sales | (1,847) | (1,818) | (3,665) | (1,878) | (5,543) | (2,006) | (7,549) |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Gross profit | 4,624 | 4,800 | 9,424 | 4,632 | 14,056 | 4,900 | 18,956 |
| Selling, general and administration | (1,955) | (2,092) | (4,047) | (1,876) | (5,923) | (2,005) | (7,928) |
| Research and development | (857) | (847) | (1,704) | (791) | (2,495) | (905) | (3,400) |
| Royalty income | 113 | 82 | 195 | 94 | 289 | 98 | 387 |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Operating profit | 1,925 | 1,943 | 3,868 | 2,059 | 5,927 | 2,088 | 8,015 |
| Net finance costs | (176) | (183) | (359) | (178) | (537) | (155) | (692) |
| Share of after tax profits of associates and joint ventures | 11 | 7 | 18 | 14 | 32 | 11 | 43 |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Profit before taxation | 1,760 | 1,767 | 3,527 | 1,895 | 5,422 | 1,944 | 7,366 |
| Taxation | (394) | (424) | (818) | (446) | (1,264) | (431) | (1,695) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | |
|--|-------|-------|-------|-------|-------|-------|--------|
| Tax rate % | 22.4% | 24.0% | 23.2% | 23.5% | 23.3% | 22.2% | 23.0% |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Profit after taxation | 1,366 | 1,343 | 2,709 | 1,449 | 4,158 | 1,513 | 5,671 |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Profit attributable to non-controlling interests | 68 | 64 | 132 | 49 | 181 | 69 | 250 |
| | | | | | | | |
| Profit attributable to shareholders | 1,298 | 1,279 | 2,577 | 1,400 | 3,977 | 1,444 | 5,421 |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Earnings per share | 26.9p | 26.3p | 53.2p | 28.9p | 82.1p | 30.1p | 112.2p |
| | | | | | | | |
| Weighted average number of shares | 4,834 | 4,855 | 4,844 | 4,837 | 4,842 | 4,798 | 4,831 |

Impact of Divestments on 2013 Core Results

| | Q1 2013 | Q2 2013 | H1 2013 | Q3 2013 | 9M 2013 | Q4 2013 | FY 2013 |
|--|---------|---------|---------|---------|---------|---------|---------|
| | £m | £m | £m | £m | £m | £m | £m |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Turnover | (216) | (245) | (461) | (236) | (697) | (206) | (903) |
| Cost of sales | 118 | 126 | 244 | 127 | 371 | 103 | 474 |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Gross profit | (98) | (119) | (217) | (109) | (326) | (103) | (429) |
| | | | | | | | |
| Selling, general and administration | 47 | 53 | 100 | 45 | 145 | 34 | 179 |
| | | | | | | | |
| Research and development | 2 | 1 | 3 | 2 | 5 | 1 | 6 |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Operating profit | (49) | (65) | (114) | (62) | (176) | (68) | (244) |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Profit before taxation | (49) | (65) | (114) | (62) | (176) | (68) | (244) |
| | | | | | | | |
| Taxation | 12 | 16 | 28 | 15 | 43 | 17 | 60 |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Profit after taxation | (37) | (49) | (86) | (47) | (133) | (51) | (184) |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Profit attributable to non-controlling interests | - | - | - | - | - | - | - |
| | | | | | | | |
| Profit attributable to shareholders | (37) | (49) | (86) | (47) | (133) | (51) | (184) |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Earnings per share | | | | | | | (3.8)p |
| | | | | | | | 4,831 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Weighted average number of shares

| | Q1 2013 | Q2 2013 | H1 2013 | Q3 2013 | 9M 2013 | Q4 2013 | FY 2013 |
|---|---------|---------|---------|---------|---------|---------|---------|
| | £m | £m | £m | £m | £m | £m | £m |
| Revised 2013 Core Results | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Turnover | 6,255 | 6,373 | 12,628 | 6,274 | 18,902 | 6,700 | 25,602 |
| Cost of sales | (1,729) | (1,692) | (3,421) | (1,751) | (5,172) | (1,903) | (7,075) |
| Gross profit | 4,526 | 4,681 | 9,207 | 4,523 | 13,730 | 4,797 | 18,527 |
| Selling, general and administration | (1,908) | (2,039) | (3,947) | (1,831) | (5,778) | (1,971) | (7,749) |
| Research and development | (855) | (846) | (1,701) | (789) | (2,490) | (904) | (3,394) |
| Royalty income | 113 | 82 | 195 | 94 | 289 | 98 | 387 |
| Operating profit | 1,876 | 1,878 | 3,754 | 1,997 | 5,751 | 2,020 | 7,771 |
| Net finance costs | (176) | (183) | (359) | (178) | (537) | (155) | (692) |
| Share of after tax profits of associates and joint ventures | 11 | 7 | 18 | 14 | 32 | 11 | 43 |
| Profit before taxation | 1,711 | 1,702 | 3,413 | 1,833 | 5,246 | 1,876 | 7,122 |
| Taxation | (382) | (408) | (790) | (431) | (1,221) | (414) | (1,635) |
| Tax rate % | 22.3% | 24.0% | 23.1% | 23.5% | 23.3% | 22.1% | 23.0% |
| Profit after taxation | 1,329 | 1,294 | 2,623 | 1,402 | 4,025 | 1,462 | 5,487 |
| Profit attributable to non-controlling interests | 68 | 64 | 132 | 49 | 181 | 69 | 250 |
| Profit attributable to shareholders | 1,261 | 1,230 | 2,491 | 1,353 | 3,844 | 1,393 | 5,237 |
| Earnings per share | 26.1p | 25.3p | 51.4p | 28.0p | 79.4p | 29.0p | 108.4p |
| Weighted average number of shares | 4,834 | 4,855 | 4,844 | 4,837 | 4,842 | 4,798 | 4,831 |

Appendix

Core Results Reconciliations - as previously reported

Three months ended 31 March 2013

| | Core results £m | Intangible amortisation £m | Intangible impairment £m | Major restructuring £m | Legal costs £m | Acquisition accounting and other £m | Total results £m |
|--|-----------------------|----------------------------------|--------------------------------|------------------------------|----------------------|--|------------------------|
| Turnover | 6,471 | | | | | | 6,471 |
| Cost of sales | (1,847) | (109) | | (20) | | | (1,976) |
| Gross profit | 4,624 | (109) | | (20) | | | 4,495 |
| Selling, general and administration | (1,955) | | | (60) | (66) | 1 | (2,080) |
| Research and development | (857) | (25) | 1 | (6) | | (17) | (904) |
| Royalty income | 113 | | | | | | 113 |
| Other operating income/(expense) | | | | | | (44) | (44) |
| Operating profit | 1,925 | (134) | 1 | (86) | (66) | (60) | 1,580 |
| Net finance costs | (176) | | | (2) | | (2) | (180) |
| Share of after tax profits of associates and joint ventures | 11 | | | | | | 11 |
| Profit before taxation | 1,760 | (134) | 1 | (88) | (66) | (62) | 1,411 |
| Taxation | (394) | 37 | | (57) | 12 | 20 | (382) |
| Tax rate % | 22.4% | | | | | | 27.1% |
| Profit after taxation | 1,366 | (97) | 1 | (145) | (54) | (42) | 1,029 |
| Profit attributable to non-controlling interests | 68 | | | | | | 68 |
| Profit attributable to shareholders | 1,298 | (97) | 1 | (145) | (54) | (42) | 961 |
| Earnings per share | 26.9p | (2.0)p | - | (3.0)p | (1.1)p | (0.9)p | 19.9p |
| Weighted average number of shares (millions) | 4,834 | | | | | | 4,834 |

Appendix

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Three months ended 30 June 2013

| | Core results £m | Intangible amortisation £m | Intangible impairment £m | Major restructuring £m | Legal costs £m | Acquisition accounting and other £m | Total results £m |
|--|-----------------------|----------------------------------|--------------------------------|------------------------------|----------------------|--|------------------------|
| Turnover | 6,618 | | | | | | 6,618 |
| Cost of sales | (1,818) | (109) | | (45) | | | (1,972) |
| Gross profit | 4,800 | (109) | | (45) | | | 4,646 |
| Selling, general and administration | (2,092) | | | (99) | (24) | (1) | (2,216) |
| Research and development | (847) | (24) | (135) | (29) | | (14) | (1,049) |
| Royalty income | 82 | | | | | | 82 |
| Other operating income/(expense) | | | | | | (25) | (25) |
| Operating profit | 1,943 | (133) | (135) | (173) | (24) | (40) | 1,438 |
| Net finance costs | (183) | | | (1) | | (2) | (186) |
| Profit on disposal of associates | | | | | | 29 | 29 |
| Share of after tax profits of associates and joint ventures | 7 | | | | | | 7 |
| Profit before taxation | 1,767 | (133) | (135) | (174) | (24) | (13) | 1,288 |
| Taxation | (424) | 36 | 35 | 135 | | 14 | (204) |
| Tax rate % | 24.0% | | | | | | 15.8% |
| Profit after taxation | 1,343 | (97) | (100) | (39) | (24) | 1 | 1,084 |
| Profit attributable to non-controlling interests | 64 | | | | | (25) | 39 |
| Profit attributable to shareholders | 1,279 | (97) | (100) | (39) | (24) | 26 | 1,045 |
| Earnings per share | 26.3p | (2.0)p | (2.1)p | (0.8)p | (0.5)p | 0.6p | 21.5p |
| Weighted average number of shares (millions) | 4,855 | | | | | | 4,855 |

Six months ended 30 June 2013

| | Core results £m | Intangible amortisation £m | Intangible impairment £m | Major restructuring £m | Legal costs £m | Acquisition accounting and other £m | Total results £m |
|--|-----------------------|----------------------------------|--------------------------------|------------------------------|----------------------|--|------------------------|
| Turnover | 13,089 | | | | | | 13,089 |
| Cost of sales | (3,665) | (218) | | (65) | | | (3,948) |
| Gross profit | 9,424 | (218) | | (65) | | | 9,141 |
| Selling, general and administration | (4,047) | | | (159) | (90) | | (4,296) |
| Research and development | (1,704) | (49) | (134) | (35) | | (31) | (1,953) |
| Royalty income | 195 | | | | | | 195 |
| Other operating income/(expense) | | | | | | (69) | (69) |
| Operating profit | 3,868 | (267) | (134) | (259) | (90) | (100) | 3,018 |
| Net finance costs | (359) | | | (3) | | (4) | (366) |
| Profit on disposal of associates | | | | | | 29 | 29 |
| Share of after tax profits of associates and joint ventures | 18 | | | | | | 18 |
| Profit before taxation | 3,527 | (267) | (134) | (262) | (90) | (75) | 2,699 |
| Taxation | (818) | 73 | 35 | 78 | 12 | 34 | (586) |
| Tax rate % | 23.2% | | | | | | 21.7% |
| Profit after taxation | 2,709 | (194) | (99) | (184) | (78) | (41) | 2,113 |
| Profit attributable to non-controlling interests | 132 | | | | | (25) | 107 |
| Profit attributable to shareholders | 2,577 | (194) | (99) | (184) | (78) | (16) | 2,006 |
| Earnings per share | 53.2p | (4.0)p | (2.0)p | (3.8)p | (1.6)p | (0.4)p | 41.4p |

| | | |
|--|-------|-------|
| Weighted average number of shares (millions) | 4,844 | 4,844 |
| | ----- | ----- |

Appendix

Three months ended 30 September 2013

| | Core results £m | Intangible amortisation £m | Intangible impairment £m | Major restructuring £m | Legal costs £m | Acquisition accounting and other £m | Total results £m |
|---|-----------------------|----------------------------------|--------------------------------|------------------------------|----------------------|--|------------------------|
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |
| Turnover | 6,510 | | | | | | 6,510 |
| Cost of sales | (1,878) | (105) | (81) | (47) | | | (2,111) |
| Gross profit | 4,632 | (105) | (81) | (47) | | | 4,399 |
| Selling, general and administration | (1,876) | | | (34) | (73) | (1) | (1,984) |
| Research and development | (791) | (25) | (71) | (2) | | (11) | (900) |
| Royalty income | 94 | | | | | | 94 |
| Other operating income/(expense) | - | | | | | (40) | (40) |
| Operating profit | 2,059 | (130) | (152) | (83) | (73) | (52) | 1,569 |
| Net finance costs | (178) | | | (1) | | (2) | (181) |
| Share of after tax profits of associates and joint ventures | 14 | | | | | | 14 |
| Profit before taxation | 1,895 | (130) | (152) | (84) | (73) | (54) | 1,402 |
| Taxation | (446) | 35 | 37 | (43) | 14 | 11 | (392) |
| Tax rate % | 23.5% | | | | | | 28.0% |
| Profit after taxation | 1,449 | (95) | (115) | (127) | (59) | (43) | 1,010 |
| Profit attributable to non-controlling interests | 49 | | | | | (8) | 41 |
| Profit attributable to shareholders | 1,400 | (95) | (115) | (127) | (59) | (35) | 969 |
| | ----- | ----- | ----- | ----- | ----- | ----- | ----- |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | |
|--|-------|--------|--------|--------|--------|--------|-------|
| Earnings per share | 28.9p | (2.0)p | (2.4)p | (2.6)p | (1.2)p | (0.7)p | 20.0p |
| Weighted average number of shares (millions) | 4,837 | | | | | | 4,837 |

Appendix

Nine months ended 30 September 2013

| | Core results £m | Intangible amortisation £m | Intangible impairment £m | Major restructuring £m | Acquisition Legal costs £m | Accounting and other £m | Total results £m |
|---|--------------------|-------------------------------|-----------------------------|---------------------------|----------------------------------|----------------------------|---------------------|
| Turnover | 19,599 | | | | | | 19,599 |
| Cost of sales | (5,543) | (323) | (81) | (112) | | | (6,059) |
| Gross profit | 14,056 | (323) | (81) | (112) | | | 13,540 |
| Selling, general and administration | (5,923) | | | (193) | (163) | (1) | (6,280) |
| Research and development | (2,495) | (74) | (205) | (37) | | (42) | (2,853) |
| Royalty income | 289 | | | | | | 289 |
| Other operating income/(expense) | - | | | | | (109) | (109) |
| Operating profit | 5,927 | (397) | (286) | (342) | (163) | (152) | 4,587 |
| Net finance costs | (537) | | | (4) | | (6) | (547) |
| Profit on disposal of associates and joint ventures | - | | | | | 29 | 29 |
| Share of after tax profits of associates and joint ventures | 32 | | | | | | 32 |
| Profit before taxation | 5,422 | (397) | (286) | (346) | (163) | (129) | 4,101 |
| Taxation | (1,264) | 108 | 72 | 35 | 26 | 45 | (978) |
| Tax rate % | 23.3% | | | | | | 23.8% |
| Profit after taxation | 4,158 | (289) | (214) | (311) | (137) | (84) | 3,123 |
| | 181 | | | | | (33) | 148 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Profit attributable to non-controlling interests

| | | | | | | | |
|--|-------|--------|--------|--------|--------|--------|-------|
| Profit attributable to shareholders | 3,977 | (289) | (214) | (311) | (137) | (51) | 2,975 |
| Earnings per share | 82.1p | (6.1)p | (4.4)p | (6.4)p | (2.8)p | (1.0)p | 61.4p |
| Weighted average number of shares (millions) | 4,842 | | | | | | 4,842 |

Appendix

Three months ended 31 December 2013

| | Core results £m | Intangible amortisation £m | Intangible impairment £m | Major restructuring £m | Legal costs £m | Acquisition accounting and other £m | Total results £m |
|---|--------------------|-------------------------------|-----------------------------|---------------------------|-------------------|--|---------------------|
| Turnover | 6,906 | | | | | | 6,906 |
| Cost of sales | (2,006) | (127) | (327) | (66) | | | (2,526) |
| Gross profit | 4,900 | (127) | (327) | (66) | | | 4,380 |
| Selling, general and administration | (2,005) | | | (107) | (89) | 1 | (2,200) |
| Research and development | (905) | (23) | (126) | (2) | | (14) | (1,070) |
| Royalty income | 98 | | | | | | 98 |
| Other operating income/(expense) | | | | | | 1,233 | 1,233 |
| Operating profit | 2,088 | (150) | (453) | (175) | (89) | 1,220 | 2,441 |
| Net finance costs | (155) | | | (2) | | (2) | (159) |
| Profit on disposal of associates and joint ventures | - | | | | | 253 | 253 |
| Share of after tax profits of associates and joint ventures | 11 | | | | | | 11 |
| Profit before taxation | 1,944 | (150) | (453) | (177) | (89) | 1,471 | 2,546 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | |
|--|-------|--------|--------|--------|--------|-------|-------|
| Taxation | (431) | 41 | 154 | 110 | (17) | 102 | (41) |
| Tax rate % | 22.2% | | | | | | 1.6% |
| Profit after taxation | 1,513 | (109) | (299) | (67) | (106) | 1,573 | 2,505 |
| Profit attributable to non-controlling interests | 69 | | | | | (25) | 44 |
| Profit attributable to shareholders | 1,444 | (109) | (299) | (67) | (106) | 1,598 | 2,461 |
| Earnings per share | 30.1p | (2.3)p | (6.2)p | (1.4)p | (2.2)p | 33.3p | 51.3p |
| Weighted average number of shares (millions) | 4,798 | | | | | | 4,798 |

Appendix

Year ended 31 December 2013

| | Core results £m | Intangible amortisation £m | Intangible impairment £m | Major restructuring £m | Legal costs £m | Acquisition accounting and other £m | Total results £m |
|---|--------------------|-------------------------------|-----------------------------|---------------------------|-------------------|--|---------------------|
| Turnover | 26,505 | | | | | | 26,505 |
| Cost of sales | (7,549) | (450) | (408) | (178) | | | (8,585) |
| Gross profit | 18,956 | (450) | (408) | (178) | - | | 17,920 |
| Selling, general and administration | (7,928) | | | (300) | (252) | | (8,480) |
| Research and development | (3,400) | (97) | (331) | (39) | | (56) | (3,923) |
| Royalty income | 387 | | | | | | 387 |
| Other operating income/(expense) | - | | | | | 1,124 | 1,124 |
| Operating profit | 8,015 | (547) | (739) | (517) | (252) | 1,068 | 7,028 |
| Net finance costs | (692) | | | (6) | | (8) | (706) |
| Profit on disposal of interest in associates and joint ventures | - | | | | | 282 | 282 |

| | | | | | | | |
|---|---------|--------|---------|--------|--------|-------|---------|
| Share of after tax profits of associates and joint ventures | 43 | | | | | | 43 |
| Profit before taxation | 7,366 | (547) | (739) | (523) | (252) | 1,342 | 6,647 |
| Taxation | (1,695) | 149 | 226 | 145 | 9 | 147 | (1,019) |
| Tax rate % | 23.0% | | | | | | 15.3% |
| Profit after taxation | 5,671 | (398) | (513) | (378) | (243) | 1,489 | 5,628 |
| Profit attributable to non-controlling interests | 250 | | | | | (58) | 192 |
| Profit attributable to shareholders | 5,421 | (398) | (513) | (378) | (243) | 1,547 | 5,436 |
| Earnings per share | 112.2p | (8.2)p | (10.7)p | (7.8)p | (5.0)p | 32.0p | 112.5p |
| Weighted average number of shares (millions) | 4,831 | | | | | | 4,831 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: March 21, 2014

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc